HRT and Bone Health: What the Evidence Shows

Educational only. Not medical advice. Bone health decisions should be based on individualized risk assessment including DEXA results, fracture history, and other risk factors. Discuss with your clinician.

In the first five to seven years after menopause, women can lose up to 20% of their bone density. This is not a gradual aging process - it is an estrogen-dependent acceleration that begins the moment your body stops producing adequate estrogen. HRT is one of the few treatments FDA-approved specifically for the prevention of postmenopausal osteoporosis, and the WHI data on fracture reduction is among the most robust evidence for any osteoporosis intervention.

The WHI estrogen-plus-progestin arm showed a 34% reduction in hip fractures and a 24% reduction in total fractures. The estrogen-only arm showed similar reductions. These are not modest effects - they are clinically significant reductions in fractures that cause disability, loss of independence, and death (hip fracture mortality in the first year is approximately 20 to 30% in older adults).

If bone protection is part of your HRT decision, the evidence is clear and strong.

Estrogen regulates the balance between bone formation (osteoblast activity) and bone resorption (osteoclast activity). When estrogen declines, osteoclast activity increases - bone is broken down faster than it is built. The spine, hip, and wrist are the most commonly affected sites. Not every woman who goes through menopause develops osteoporosis, but the hormonal shift is a significant and well-documented risk factor.

Women with premature menopause (before 40) or early menopause (before 45) face the highest bone loss risk because the acceleration starts decades earlier.

Bisphosphonates (alendronate, risedronate). The most commonly prescribed bone-specific medications. Effective for both prevention and treatment. Have a residual effect after discontinuation (they incorporate into bone tissue). Often first-line for patients whose primary concern is bone density without other menopausal symptoms.

Denosumab (Prolia). A biologic agent that inhibits osteoclast activity. Effective but requires regular injections and has a significant rebound effect if discontinued (rapid bone loss when stopped). Typically reserved for higher-risk patients.

HRT. Prevents bone loss and reduces fractures. Also treats vasomotor symptoms, GSM, and other menopausal concerns. The advantage: it addresses multiple menopausal problems simultaneously. The limitation: bone-protective benefits are maintained only while on HRT and are lost after discontinuation (unlike bisphosphonates).

The practical implication: for women who need both symptom relief and bone protection, HRT is the most efficient single intervention. For women whose primary concern is bone density without other symptoms, bisphosphonates may be more appropriate. For women stopping HRT who have osteoporosis risk, transitioning to a bisphosphonate protects the bone density that HRT maintained.

Dual-energy X-ray absorptiometry (DEXA) is the standard for measuring bone mineral density. Results are reported as T-scores: normal is above negative 1.0, osteopenia (reduced density) is negative 1.0 to negative 2.5, and osteoporosis is negative 2.5 or lower.

Baseline DEXA is recommended for all women at age 65, or earlier for those with risk factors: premature or early menopause, low body weight, family history of hip fracture, prolonged corticosteroid use, or smoking. If you are starting HRT partly for bone protection, a baseline DEXA at the start of treatment and follow-up at 1 to 2 years documents the benefit.

The FRAX tool (fractureriskassessment.org) calculates your 10 year fracture risk based on clinical risk factors and can include DEXA results. This helps guide treatment decisions - a woman with osteopenia and a high FRAX score may warrant treatment even though she does not meet the T-score threshold for osteoporosis.

HRT works best for bone protection alongside adequate calcium (1,000 to 1,200mg daily, preferably from dietary sources), sufficient vitamin D (600 to 800 IU daily, check 25-OH vitamin D levels and supplement to maintain above 30 ng/mL), weight-bearing exercise (walking, stair climbing, resistance training), and smoking cessation and limited alcohol intake.

These are foundational for bone health regardless of pharmacological treatment. Resistance training deserves special emphasis - it loads bones at the spine and hip (the highest-risk fracture sites) and builds the muscle strength that prevents falls.

• When should I get a baseline DEXA scan?
• Given my bone density and risk factors, is HRT, a bisphosphonate, or both appropriate?
• If I stop HRT, what is the plan for ongoing bone protection?
• What calcium and vitamin D intake do you recommend for me specifically?
• Should I have a FRAX risk assessment?